|

Survival and Side Effects: Insights from RIOMeso on Mesothelioma Treatment

ByHolly Zink
Survival and Side Effects: Insights from RIOMeso on Mesothelioma Treatment

Mesothelioma is a hard diagnosis, especially in Australia where asbestos-related diseases are a big concern. With only a 10% survival rate over five years, finding effective treatments is super important.

Recently, a standard treatment in unresectable pleural mesothelioma has surfaced following successful trials. A study called RIOMeso has assessed how this treatment impacts survival and side effects in real-world scenarios.

Navigating Mesothelioma Treatment Realities

Lately, a common treatment for hard-to-remove pleural mesothelioma has surfaced. It involves using ipilimumab and nivolumab together. This treatment became a standard after successful trials. The RIOMeso study looked at how well this treatment works and what side effects it brings in real life.

The study checked out 119 patients from 11 places in Australia. Most were guys around 72 years old, and many had been around asbestos. About 75% got this treatment first, and everyone survived about 14.5 months on average, whether they got it first or later.

The type of mesothelioma didn’t seem to change how long people lived with this treatment. But here’s the thing: about a fourth of the patients had some pretty bad side effects. Three people even passed away because of the treatment, and lots of folks got colitis, which is when your colon gets swollen.

The study showed that this combo treatment led to lower survival rates and more bad effects than what was seen in earlier trials. It’s the first time anyone’s really looked at how this combo works outside of controlled tests.

Investigating Immunotherapy Impact in Real-Life Mesothelioma Care

People with pleural mesothelioma haven’t had many breakthroughs in treatment. They tried adding bevacizumab to chemotherapy, which seemed okay. But lately, there’s been more hope in using immunotherapy, especially in later stages.

One big trial, CheckMate 743, said that using ipilimumab and nivolumab first helped folks live longer. But even though this sounded good, only about 23% were still alive after three years. And some folks had more problems, especially older ones and those with certain types of mesothelioma.

Other studies mixing pembrolizumab with chemotherapy also helped people live longer. This shows that immunotherapy might be a real help for treating mesothelioma.

Starting from July 2021, Aussies got access to this ipilimumab and nivolumab treatment. That’s when the RIOMeso study kicked in to see how well this new treatment really does in everyday life in Australia.

What this study found tells us that while treatments from tests seem hopeful, they bring their own troubles when used in real life. It’s a reminder that there’s more to learn and adjust when using these treatments outside of research. Understanding these differences is key in making treatments better and in managing what patients and their helpers can expect.

Source:

McNamee, Nicholas, Catriona Harvey, Lauren Gray, Trisha Khoo, Lavanya Lingam, Betty Zhang, Udit Nindra, et al. “Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso.” Journal of Thoracic Oncology, November 28, 2023. https://doi.org/10.1016/j.jtho.2023.11.014.

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | | |

    Mesothelioma Nurses Ready for New Cases in Australia

    ByAlex Strauss

    Australia is bracing for an expected new wave of mesothelioma cases in the next decade and the Lung Foundation of Australia is taking action now to get ready. The Foundation has paid for ten nurses from around the country to receive specialized training in helping patients and families cope with mesothelioma. The nurses, who have recently completed the training, are now equipped to lead treatment planning for these complex cancer patients and to help other nurses do the same. Pleural mesothelioma is an aggressive cancer that occurs in the lining around the lungs. It is caused by exposure to asbestos dust, a toxin that was once alarmingly prevalent in Australia where it was mined and heavily used in construction. Because…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…